New drug cocktail targets childhood cancers with missing proteins

NCT ID NCT05407441

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a combination of three drugs—tazemetostat, nivolumab, and ipilimumab—in children with rare tumors that lack the INI1 or SMARCA4 proteins. The goal is to find a safe dose and see if the drugs can shrink tumors. About 49 children with specific tumor types are being enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
tazemetostat, nivolumab, and ipilimumab
What this could lead to
If this works, it could offer a new treatment option for children with rare, hard-to-treat tumors that lack certain proteins.
What could go wrong
This is an early-phase trial with only 49 participants, so results may not apply broadly. The drug combination can cause serious side effects, and it's not yet known if it will shrink tumors effectively.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATYPICAL TERATOID/RHABDOID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Boston Children's Hospital

    Boston, Massachusetts, 02115, United States

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Texas Children's Hospital

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.